Phase I clinical trial of a recombinant blood stage vaccine candidate for Plasmodium falciparum malaria based on MSP1 and EBA175

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Chitnis, Chetan E ^a,g   Mukherjee, Paushali ^a   Mehta, Shantanu ^b   Yazdani, Syed Shams ^a   Dhawan, Shikha ^a   Shakri, Ahmad Rushdi ^a   Bharadwaj, Rukmini ^a   Gupta, Puneet Kumar ^a   Hans, Dhiraj ^a   Mazumdar, Suman ^a   Singh, Bijender ^a   Kumar, Sanjeev ^a   Pandey, Gaurav ^b   Parulekar, Varsha ^f   Imbault, Nathalie ^c   Shivyogi, Preethi ^e   Godbole, Girish ^e   Mohan, Krishna ^d   Leroy, Odile ^c   Singh, Kavita ^b   Chauhan, Virander S ^a   more..

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY ICGEB   (India)

^b Malaria Vaccine Development Program   (India)

^c European Vaccine Initiative   (Germany)

^d Bharat Biotech International Ltd   (India)

^e Lotus Labs Private Ltd   (India)

^f Diagnosearch Laboratory Services   (India)

^g INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EBA175 PROTEIN; HEPATITIS B VACCINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; IMMUNOLOGICAL ADJUVANT; JAIVAC 1; LACTATE DEHYDROGENASE; MALARIA VACCINE; MONTANIDE ISA 720; MSP 1 PROTEIN; PFF2 ANTIBODY; PFF2 PROTEIN; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; ERYTHROCYTE-BINDING ANTIGEN 175, PLASMODIUM; IMMUNOGLOBULIN G; MANNIDE MONOOLEATE; MANNITOL; MEROZOITE SURFACE PROTEIN 1; OLEIC ACID; PARASITE ANTIGEN;

ADULT; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ANTIMALARIAL ACTIVITY; ARTICLE; ASSAY; COHORT ANALYSIS; CONTROLLED STUDY; DELTOID MUSCLE; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERANCE; FEVER; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOFLUORESCENCE TEST; IMMUNOGENICITY; INDIAN; MALAISE; MALARIA FALCIPARUM; MALARIA VACCINATION; MALE; MEROZOITE; MYALGIA; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PLASMODIUM FALCIPARUM GROWTH INHIBITION ASSAY; RANDOMIZED CONTROLLED TRIAL; SCHIZONT; SEROCONVERSION; SINGLE BLIND PROCEDURE; VACCINATION; ADOLESCENT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; FEMALE; IMMUNOLOGY; INDIA; MALARIA, FALCIPARUM; MIDDLE AGED; MULTICENTER STUDY; PLASMODIUM FALCIPARUM;

PLASMODIUM FALCIPARUM;

ADOLESCENT; ADULT; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HEPATITIS B VACCINES; HUMANS; IMMUNOGLOBULIN G; INDIA; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; MANNITOL; MEROZOITE SURFACE PROTEIN 1; MIDDLE AGED; OLEIC ACIDS; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS;

EID: 84928721604     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0117820     Document Type: Article

References (40)

1. World Health Organization Media Centre: Factsheet on the World Malaria Report 2013 December 2013, Available: http://www.who.int/malaria/media/world-malaria-report-2013/en/. Accessed 2015 January 07.
2. The malERA Consultative Group on Vaccines. (2011) A Research Agenda for Malaria Eradication: Vaccines. PLoS Med 8(1): e1000398. doi: 10.1371/journal.pmed.1000398 PMID: 21311586
3. McCallum FJ, Persson KEM, Mugyenyi CK, Fowkes FJI, Simpson JA, et al. (2008) Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum. PLoS ONE 3(10)e3571. doi:10.1371/journal.pone.0003571 PMID: 18958278
4. Sim BK, Chitnis CE, Wasniowska K, Hadley TJ, Miller LH (1994) Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum. Science 264: 1941-1944. PMID: 8009226
5. Narum DL, Haynes J D, Fuhrmann S, Moch K, Liang H, et al. (2000). Antibodies against the Plasmodium falciparum receptor-binding domain of EBA-175 block invasion pathways that do not involve sialic acids. Infect Immun 68:1964-1966. PMID: 10722589
6. Pandey KC, Singh S, Pattnaik P, Pillai CR, Pillai U, et al. (2002) Bacterially expressed and refolded receptor binding domain of Plasmodium falciparum EBA-175 elicits invasion inhibitory antibodies. Mol Biochem Parasitol 123:23-33. PMID: 12165386
7. Nikodem D, Davidson E (2000) Identification of a novel antigenic domain of Plasmodium falciparum merozoite surface protein-1 that specifically binds to human erythrocytes and inhibits parasite invasion, in vitro. Mol Biochem Parasitol 108:79-91. PMID: 10802320
8. Blackman MJ, Holder AA (1992) Secondary processing of the Plasmodium falciparum merozoite surface protein-1 (MSP1) by a calcium-dependent membrane-bound serine protease: shedding of MSP133 as a noncovalently associated complex with other fragments of the MSP1. Mol Biochem Parasitol Feb 50(2):307-15. PMID: 1741018
9. Al-Yaman F, Genton B, Kramer KJ, Chang SP, Hui GS, et al. (1996) Assessment of the role of naturally acquired anti- body levels to Plasmodium falciparum merozoite surface protein-1 in protecting Papua New Guinean children from malaria morbidity. Am J Trop Med Hyg 54:443-448 PMID: 8644896
10. Egan AF, Burghaus P, Druilhe P, Holder AA, Riley EM (1999) Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro. Parasite Immunol 21:133-139 PMID: 10205793
11. Egan AF, Morris J, Barnish G, Allen S, Greenwood BM, et al. (1996) Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C- terminal fragment of the merozoite surface antigen, PfMSP-1. J Infect Dis 173:765-769 PMID: 8627050
12. Riley EM, Allen SJ, Wheeler JG, Blackman MJ, Bennett S, et al. (1992) Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) of Plasmodium falciparum are associated with reduced malaria morbidity. Parasite Immunol 14:321-337. PMID: 1625908
13. Keitel WA, Kester KE, Atmar RL, White AC, Bond NH, et al. (1999) Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid. Vaccine 18: 531-39. PMID: 10519944
14. Ockenhouse CF, Angov E, Kester KE, Diggs C, Soisson L, et al. (2006) Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. Vaccine 24: 3009-17. PMID: 16356603
15. Ogutu BR, Apollo OJ, McKinney D, Okoth W, Siangla J, et al. (2009) Blood Stage Malaria Vaccine Eliciting High Antigen-Specific Antibody Concentrations Confers No Protection to Young Children in Western Kenya. PLoS ONE 4: e4708. doi: 10.1371/journal.pone.0004708 PMID: 19262754
16. Sheehy SH, Duncan CJ, Elias SC, Collins KA, Ewer KJ, et al. (2011) Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther 19: 2269-76. doi: 10.1038/mt.2011.176 PMID: 21862998
17. Biswas S, Choudhary P, Elias SC, Miura K, Milne KH, et al. (2014) Assessment of humoral immune responses to blood-Stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure. PLoS One 9:e107903. doi: 10.1371/journal.pone.0107903 PMID: 25254500
18. El Sahly HM, Patel SM, Atmar RL, Lanford TA, Dube T, et al. (2010) Safety and Immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 region II malaria vaccine in healthy adults living in an area where malaria is not endemic. Clinical and Vaccine Immunology, p. 1552-1559.
19. Miles AP, McClellan HA, Rausch KM, Zhu D, Whitmore MD, et al. (2005) Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations. Vaccine 23:2530-39. PMID: 15752840
20. Lawrence GW, Saul A, Giddy AJ, Kemp R, Pye D (1997) Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720. Vaccine 15:176-78. PMID: 9066035
21. Genton B, Al-Yaman F, Anders R, Saul A, Brown G, et al. (2000) Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea. Vaccine 18: 2504-11. PMID: 10775784
22. Aucouturier J, Dupuis L, Deville S, Ascarateil S, Ganne V (2002) Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines 1:111-8. PMID: 12908518
23. Fox CB, Anderson RC, Dutill TS, Goto Y, Reed SG, et al. (2008) Monitoring the effects of component structure and source and formulation stability and adjuvant activity of oil-in-water emulsions. Colloids Surf B: Biointerfaces 65: 98-105. doi: 10.1016/j.colsurfb.2008.03.003 PMID: 18440205
24. Makler MT, Ries JM, Williams JA, Bancroft JE, Piper RC, et al. (1993) Parasite lactate dehydrogenase as an assay for Plasmodiumfalciparum drug sensitivity. Am J Trop Med Hyg 48:739-41. PMID: 8333566
25. Roestenberg M, Remarque E, Jonge ED, Hermsen R, Blythman H, et al. (2008) Safety and Immunogenicity of a Recombinant Plasmodium falciparum AMA1 Malaria Vaccine Adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS One,; 3(12): e3960. doi: 10.1371/journal.pone.0003960 PMID: 19093004
26. Audran R, Cachat M, Lurati F (2005) Phase I Malaria Vaccine Trial with a Long Synthetic Peptide Derived from the Merozoite Surface Protein 3 Antigen. InfectImmun; 73 (12):8017-8026. PMID: 16299295
27. Elliott SL, Suhrbier A, Miles JJ, Lawrence G, Pye SJ, et al. (2008) Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis. J Virol. Feb; 82(3):1448- 1457. PMID: 18032491
28. Hermsen CC, Verhage DF, Telgt DSC, Karina T, Bousema JT, et al. (2007) Glutamate- rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial. Vaccine. Apr 12; 25(15):2930-2940.
29. Hu J, Chen Z, Gu J, Wan M, Shen Q, et al. (2008) Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in Montanide ISA 720 in healthy adults. PLoS ONE. 2008 Apr 9; 3(4):e1952. doi: 10.1371/journal.pone.0001952 PMID: 18398475
30. Malkin E, Hu J, Li Z, Chena Z, Bi X, et al. (2008) A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria. Vaccine. Dec 9; 26(52):6864 -6873. doi:10.1016/j.vaccine.2008.09.081 PMID: 18930094
31. Lawrence G, Cheng QQ, Reed C, Taylor D, Stowers A, et al. (2000) Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers. Vaccine. Mar 17; 18(18):1925-1931. PMID: 10699342
32. Oliveira GA, Wetzel K, Calvo-Calle JM, Nussenzweig R, Schmidt A, et al. (2005) Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial. Infect Immun. Jun; 73(6):3587-3597 PMID: 15908388
33. Saul A, Lawrence G, Smillie A, Rzepczyk CM, Reed C, et al. (1999) Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Vaccine. Aug 6; 17(23-24):3145-3159. PMID: 10471187
34. Genton B, Al-Yamana F, Betuela I, Anders RF, Saul A, et al. (2003) Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children. Vaccine. Dec 8; 22(1):30-41. PMID: 14604568
35. Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, et al. (2002) A recombinant blood stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a Phase 1-2b trial in Papua New Guinea. Am. J. Infect Dis; 185:820-7. PMID: 11920300
36. Ellis RD, Sagara I, Doumbo O, Wu Y (2010) Blood stage vaccines for Plasmodium falciparum: current status and the way forward. Hum Vaccine 6:627-34. PMID: 20519960
37. Hodder AN, Crewther PE, Anders RF (2001) Specificity of the protective antibody response to apical membrane antigen 1. Infect Immun 69:3286-94. PMID: 11292751
38. Arévalo-Herrera M, Vera O, Castellanos A, Céspedes N, Soto L, et al (2011) Preclinical vaccine study of Plasmodium vivax circumsporozoite protein derived-synthetic polypeptides formulated in montanide ISA 720 and montanide ISA 51 adjuvants. Am J Trop Med Hyg 84:21-7. doi: 10.4269/ajtmh.2011.10-0110 PMID: 21292874
39. Pierce MA, Ellis RD, Martin LB, Malkin E, Tierney E, et al. (2010) Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults. Vaccine 28:2236-42. doi: 10.1016/j.vaccine.2009.12.049 PMID: 20051276
40. Dolan SA, Miller LH, Wellems TE (1990) Evidence for a switching mechanism in the invasion of erythrocytes by Plasmodium falciparum. J Clin Invest 86: 618-624. PMID: 2200806